Students Research in Progress
Sunday, October 13, 2024
12:45 PM–02:15 PM
Abstract
Introduction:
Guideline directed medical therapy (GDMT) for heart failure with preserved ejection fraction (HFpEF) now includes sodium-glucose cotransporter 2 inhibitors (SGLT2i), mineralocorticoid receptor antagonists (MRAs), angiotensin II receptor blockers (ARBs), and/or angiotensin receptor-neprilysin inhibition (ARNI). Data on contemporary use of GDMT in HFpEF are limited. The aim of this study is to evaluate outpatient GDMT utilization for HFpEF following the release of the 2022 AHA/ACC/HFSA guideline.
Research Question or Hypothesis: What are the GDMT utilization patterns among ambulatory patients with HFpEF?
Study Design: This IRB-approved study is a retrospective chart review of ambulatory care patients with an active diagnosis of HFpEF (left ventricular ejection fraction > 50%) from June 1, 2022 through June 1, 2023.
Methods: Patients 18 years of age or older being followed by one of three cardiology clinics and/or two primary care clinics within a large academic center were included. The primary endpoints are the percentage of eligible patients with active ambulatory prescriptions for SGLT2i, MRAs, ARBs, and ARNI. Secondary endpoints include HF hospitalization and mortality rates. Descriptive statistics will be utilized to report patient characteristics and study endpoints. Logistic regression will be used to identify independent factors associated with GDMT utilization. A two-tailed p-value <0.05 will be considered statistically signi?cant.
Results: A total of 366 patients met inclusion criteria while an additional 192 were excluded. A total of 174 patients will be included in the final analysis. Of these patients, 162 (93.1%) were followed by one of the three cardiology clinics, while 12 (6.9%) were followed by one of the two prespecified primary care clinics only. Additional data collection and statistical analysis are ongoing.
Conclusion: This study will reveal a single center’s experience with ambulatory GDMT use among the HFpEF population. Information gleaned from final results will lead to quality improvement initiatives and outcomes research aimed at optimizing care for patients with HFpEF.
Presenting Author
Maryam Beirami B.S.University of South Florida Health Taneja College of Pharmacy
Authors
Leilani Colon B.S.
University of South Florida
Cyrille Cornelio Pharm.D.
University of Oklahoma College of Pharmacy
Mariam Mckee B.S.
University of South Florida Health Taneja College of Pharmacy
Aimon Miranda PharmD, BCPS
University of South Florida
Matthew Nguyen B.S.
University of South Florida Health Taneja College of Pharmacy
Kevin Olson MBA, PharmD, CPh
University of South Florida Taneja College of Pharmacy
Jerica Singleton Pharm.D.
University of South Florida Health Taneja College of Pharmacy